Pfizer (NYSE:PFE) announced Thursday that a late-stage trial for Hympavzi, its once-weekly injectable for bleeding disorder ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. | ...

Pfizer Inc. (NYSE:PFE) announced encouraging results from its Phase 3 clinical trial of HYMPAVZI, a potential new treatment for patients with hemophilia A or B who develop inhibitors—a major ...

Hemophilia A, a lifelong bleeding disorder, often causes spontaneous or injury-related bleeding, most commonly in large ...

Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...

Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

In Hooghly district, haemophilia injections have not been available at either Chinsurah Imambara Hospital or Arambagh Medical ...